A new era in SMA treatment has arrived — with a hefty price tag attached. Scholar Rock's Isembyld has become the first therapy approved to directly target muscle loss in spinal muscular atrophy (SMA), a rare genetic disease that causes progressive motor neuron loss and muscle wasting. The company launched the drug immediately following FDA approval and set the net annual cost at approximately $310,000 for a typical patient, though the final figure varies by weight and insurance coverage.

Isembyld works by selectively blocking myostatin, a protein that limits muscle growth, with the goal of boosting muscle mass and strength. It's designed to be used alongside existing SMN2-targeting therapies — not as a standalone — and is approved for adults and children over 2 years of age currently on those treatments. In a late-stage trial, the combination significantly improved motor skills compared to placebo.

By the Numbers:

• ~$310,000 net annual cost per typical patient
• $11,659 wholesale acquisition cost per single-use vial
• ~3 vials administered every 4 weeks for patients in the 35–45 kg range
• Approved for all adults and children over 2 years with SMA on SMN2-targeting therapy

Why it matters: SMA is a devastating and irreversible condition, and Isembyld fills a critical gap by addressing muscle loss directly — something no approved therapy has done before. But at $310K/year, access and affordability will be key hurdles as the drug rolls out to patients.